VNRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
VolitionRx Ltd is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some encouraging operating news, but the overall setup is not strong enough to justify an immediate buy: the trend is only neutral, there is no strong proprietary buy signal, analysts have turned more cautious, and the recent reverse split is a negative shareholder signal. For an impatient investor who does not want to wait for an ideal entry, this is still a hold rather than a buy.
Current price is 2.73 with a 4.51% regular-session decline and a small pre-market bounce of 1.39%. The MACD histogram is positive at 0.11 but contracting, which suggests bullish momentum is fading. RSI_6 is 55.7, a neutral reading with no strong overbought or oversold signal. Moving averages are converging, which points to a consolidating rather than trending market. The key pivot is 2.605, with resistance at 3.123 and 3.442 and support at 2.088 and 1.769. Overall, the technical picture is mixed to neutral, not a clear long-term entry signal.
["Q1 2026 revenue grew 300% year over year to $1 million.", "The company expects a $5 million milestone payment upon publication of the Nu.Q Vet manuscript for cats.", "Management is in discussions with more than a dozen global diagnostic and liquid biopsy companies for possible commercial partnerships.", "Capture-Seq has shown over 95% sensitivity in Stage I and II cancer detection, which supports the long-term product story."]
["D. Boral Capital downgraded the stock to Hold from Buy on 2026-04-20.", "The downgrade specifically cited the 1-for-20 reverse stock split, which is typically viewed as a sign of financial stress and listing pressure.", "No strong hedge fund or insider accumulation trend is present.", "The stock recently fell 4.51% in regular trading, showing weak near-term price action."]
Latest available quarter: Q1 2026. Revenue increased 300% year over year to $1 million, which is a meaningful growth improvement from a very small base. The quarter also included progress on commercialization and partnership discussions, plus a potential $5 million milestone opportunity. Even so, the absolute revenue level remains small, so while the growth trend is positive, the business is still early and not yet showing large-scale financial traction.
Analyst sentiment has softened recently. On 2026-04-20, D. Boral Capital downgraded VNRX to Hold from Buy, citing the reverse split. Earlier, on 2026-04-02, H.C. Wainwright kept a Buy rating but cut the price target to $1 from $1.50 after Q4 results, reflecting a more cautious view despite expecting possible licensing deals in 2026. Overall Wall Street is mixed, with the more recent tone leaning cautious rather than constructive.
